Available online 16 March 2024, 117523

At the core of fatty liver disease is a combination of metabolic dysfunctions.

To improve metabolic health it is imperative to apply lifestyle interventions.

Drugs that offer pleiotropic activity in different disease states should be used next.

The focus should switch from single morbidities to the simultaneous treatment of multiple comorbidities.

Drugs should target the inflammatory pathway at the core of multiple comorbidities and aging.

Therapy should also target liver fibrosis, since cardiovascular disease increases as liver fibrosis worsens.

Altered metabolic function has many detrimental effects on the body that can manifest as cardiovascular and liver diseases. Traditional approaches to understanding and treating metabolic dysfunction-associated disorders have been organ-centered, leading to silo-type disease care. However, given the broad impact that systemic metabolic dysfunction has on the human body, approaches that simultaneously involve multiple medical specialists need to be developed and encouraged to optimize patient outcomes. In this review, we highlight how several of the treatments developed for cardiac care may have a beneficial effect on the liver and vice versa, suggesting that there is a need to target the disease process, rather than specifically target the cardiovascular or liver specific sequelae of metabolic dysfunction.

Steatosis

Steatohepatitis

Diabetes mellitus

Metabolic syndrome

Fatty liver disease

Obesity

© 2024 The Author(s). Published by Elsevier B.V.